Health Ministry: Draft proposes drug licence suspension

The Ministry of Health and Family Welfare has proposed immediate licence suspension for the manufacture of drugs that fail specified quality tests, with restoration dependent on verified corrective action. Its draft notification, G.S.R. 956(E), dated 28 October 2026, would require the relevant central or state licensing authority to act upon receiving a Government Analyst’s certificate identifying the quality failure.

The proposal would amend the Drugs Rules, 1945. It is a draft for public consultation, not an operative suspension order against any manufacturer. The ministry’s notification states that the amendments would take effect on their final publication in the Official Gazette.

Government test report would trigger suspension

Under the proposed addition to Rule 85, the Central Licensing Approving Authority or State Licensing Authority, as applicable, would have to immediately suspend the manufacturing licence for the drug concerned when a Government Analyst reports that it is not of standard quality on specified parameters.

The notification lists assay, dissolution, related substances, impurities and sterility. These are the grounds specified for the new immediate-suspension provision under this rule, rather than an unrestricted reference to every possible quality defect.

Assay measures the amount of active ingredient, while dissolution assesses how a medicine releases that ingredient, CNBC-TV18 explained in its report on the proposal. DD News, reporting on 5 November 2026, described the listed parameters as essential to assessing medicines’ quality, safety and performance.

The ministry’s draft makes the analyst’s certificate the trigger for regulatory action. The proposed wording requires suspension; it does not simply give the licensing authority an additional discretionary option. It refers to the licence granted to manufacture the drug concerned, rather than expressly ordering the closure of every manufacturing activity at a facility.

Ministry identifies a gap before regulatory action

The ministry said the existing procedure for suspending or cancelling a manufacturing licence includes issuing a show-cause notice, according to DD News. Such a notice gives the licence holder an opportunity to explain why the proposed action should not be taken.

That procedure can leave a gap between identifying a substandard drug and initiating regulatory action, the ministry said, according to DD News. During that interval, the medicine may remain in circulation. The ministry presented the proposed amendment as a way to intervene promptly and prevent continued manufacture and distribution of substandard medicines.

That is the government’s stated rationale, not a measured outcome of the proposal. The notification does not provide an estimate of how many licences would be affected or quantify the time that immediate suspension would save.

The draft’s legal mechanism is a manufacturing-licence suspension. It does not set out a new recall timetable or establish that products already distributed would automatically be removed from the market when the suspension takes effect.

Two rules have differently worded triggers

The ministry proposes parallel suspension provisions under Rules 85 and 122O, but their wording differs in scope.

The proposed Rule 85 provision expressly links immediate suspension to a finding involving assay, dissolution, related substances, impurities or sterility. The proposed addition to Rule 122O instead refers to a Government Analyst’s opinion that the drug is not of standard quality, without repeating that list of parameters.

Both provisions would operate notwithstanding the existing sub-rules identified in the draft. Both would require the relevant licensing authority to suspend the manufacturing licence for the drug concerned and keep it suspended until the licence holder addresses the failure to the authority’s satisfaction.

The distinction matters when describing the proposal: the listed tests define the trigger in the new Rule 85 provision, while the proposed Rule 122O provision uses broader quality-failure wording. The notification also proposes consequential cross-reference changes in both rules.

Restoration would require verified corrective action

A manufacturer could not secure restoration merely by submitting an explanation, under the ministry’s proposed provisions. The licence holder would need to investigate the underlying cause of the failure and implement Corrective Action and Preventive Action, or CAPA.

In practical terms, the draft requires both identifying why the quality problem occurred and taking measures to address it and prevent recurrence. The licensing authority would have to be satisfied with that work.

The notification separately states that suspension could be revoked only after the corrective and preventive measures have been implemented and duly verified by the authority. It does not prescribe a fixed suspension period or an automatic restoration date.

The Central Licensing Approving Authority could also seek the root-cause analysis, corrective and preventive measures, investigation report and details of the State Licensing Authority’s final action, according to the draft. This would give the central authority access to the record of how a case was investigated and resolved.

Test reports would reach regulators and companies

The ministry also proposes amending Form 13, which DD News identifies as the Government Analyst’s test-report form.

The draft would add a copy-distribution list covering the Drugs Controller General of India; the state or Union Territory drug-control authority responsible for the location of the manufacturing site; and the manufacturer and marketer named on the label.

The ministry said the reporting change would improve coordination and accountability, according to DD News. The proposed wording places both the manufacturer and marketer in the report’s distribution chain, alongside the national and relevant local regulator.

The notification says the draft follows consultation with the Drugs Technical Advisory Board and invites objections and suggestions from any person. The central government will consider submissions received within 30 days of the date on which copies of the Gazette containing the draft are made available to the public. That availability date, rather than the notification’s signing date alone, determines the consultation period.